Background: Many factors can negatively affect growth in thalassemic patients, and hypogonadism has been considered as the main factor responsible for their pubertal growth failure. Objective: To evaluate the influence of hypogonadism and its treatment on pubertal growth and final height in thalassemic patients. Methods: We compared the growth of 28 hypogonadal thalassemic patients in whom puberty was induced to that of 25 patients in whom puberty occurred spontaneously. Results: In both groups of patients we observed reduced peak height velocity (induced puberty: females 4.9 ± 2.1, males 6.0 ± 1.8 cm/year; spontaneous puberty: females 6.1 ± 1.5, males 7.3 ± 2.1 cm/year) and pubertal height gain (induced puberty: females 11.3 ± 4.0, males 18.0 ± 4.5 cm/year; spontaneous puberty: females 15.8 ± 2.7, males 18.1 ± 5.3 cm/year) and a short final height (induced puberty: females –1.8 ± 0.7, males –2.1 ± 1.0 SDS; spontaneous puberty: females –2.3 ± 1.0, males –1.9 ± 1.0 SDS). Conclusions: Poor pubertal growth is present in thalassemic patients regardless of hypogonadism. Other factors are responsible for the reduced growth spurt and the final short stature observed in these patients.

1.
Caruso-Nicoletti M, De Sanctis V, Capra M, et al: Short stature and body proportion in thalassemia. J Pediatr Endocrinol Metab 1998;11(suppl 3):811–816.
2.
Kattamis C, Liakopoulou T, Kattamis A: Growth and development in children with thalassemia major. Acta Paediatr Scand Suppl 1990;366:111–117.
3.
De Sanctis V, Urso L: L’accrescimento staturale nella talassemia. Minerva Pediatr 1997;49:121–128.
4.
De Sanctis V, Atti G, Banin P, et al: Growth in thalassemia major. Acta Med Auxol 1991;23:29–36.
5.
De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B: Effect of different treatment regimens on linear growth and final height in β-thalassemia major. Clin Endocrinol 1994;40:791–798.
6.
Rodda CP, Reid ED, Johnson S, Doery J, Matthews R, Bowden DK: Short stature in homozygous beta-thalassemia is due to disproportionate truncal shortening. Clin Endocrinol 1995;42:587–592.
7.
Kletzky OA, Costin G, Marrs RP, Bernstein G, March CM, Mishell DR Jr: Gonadotropin insufficiency in patients with thalassemia major. J Clin Endocrinol Metab 1979;48:901–905.
8.
Wang C, Tso SC, Todd D: Hypogonadotropic hypogonadism in severe beta-thalassemia: Effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989;68:511–516.
9.
De Sanctis V, on behalf of the Italian Working Group on Endocrine Complications in Non-Endocrine Diseases: Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995;42:581–586.
10.
Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein H: Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 method). London, Academic Press, 1975.
11.
Tanner JM, Whitehouse RH: Clinical and longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976;51:170–179.
12.
Buckler JMH, Wild J: Longitudinal study of height and weight at adolescence. Arch Dis Child 1987;62:1224–1232.
13.
Buckler JMH: A Longitudinal Study of Adolescent Growth. London, Springer, 1990.
14.
Borgna-Pignatti C, De Stefano P, Zonta L, et al: Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150–155.
15.
Roth C, Pekrun A, Bartz M, et al: Short stature and failure of pubertal development in thalassemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997;156:777–783.
16.
Karlberg J, Kwan C, Gelander L, Albertsson-Wikland K: Pubertal growth assessment. Horm Res 2003;60:27–35.
17.
Filosa A, Di Maio S, Baron I, Esposito G, Galati MG: Final height and body disproportion in thalassemic boys and girls with spontaneous or induced puberty. Acta Paediatr 2000;89:1295–1301.
18.
Lederman HM, Choen A, Lee JW, Freedman MH, Gelfrand EW: Desferrioxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1968;64:748–753.
19.
Llados i Vallory EA, Girot R, Lenoir G, et al: Studies of variation of subcutaneously infused desferrioxamine and iron movements in thalassemia children. Eur J Pediatr 1989;148:503–506.
20.
Brill PW, Winchester P, Giardina PI, Cunningham-Rundles S: Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 1991;156:561–565.
21.
De Virgiliis S, Congia M, Frau F, et al: Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988;113:661–669.
22.
Olivieri NF, Koren G, Harris J, et al: Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48–56.
23.
De Sanctis V, Pinamonti A, Di Palma A, et al: Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368–372.
24.
De Sanctis V, Stea S, Savarino L, et al: Growth hormone secretion and bone histomorphometric study in thalassemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998;11:827–833.
25.
Caruso-Nicoletti M, De Sanctis V, Cavallo L, et al: Management of puberty for optimal auxological results in β-thalassemia. J Pediatr Endocrinol Metab 2001;14:939–944.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.